Investor Presentation for the quarter ended March 31, 2026

Metropolis Healthcare reported strong Q4 & FY26 results with MHL Group revenue of Rs 425 Cr in Q4 (+23% YoY) and Rs 1,646 Cr for FY26 (+24% YoY). Organic EBITDA grew 27% YoY in Q4 to Rs 107 Cr with margins expanding to 27.2%, while full-year organic EBITDA reached Rs 392 Cr at 25.9% margins, reflecting significant operating leverage. Patient volumes grew 9% YoY and test volumes 9% YoY in Q4 organically. B2C revenue grew 14% YoY and B2B grew 13% YoY for the year, while TruHealth delivered 21% YoY growth contributing 19% of revenue. Specialty testing grew 16% YoY with 37% revenue contribution. The company completed integrations of DAPIC Dehradun, Scientific Pathology Agra, and Ambika Kolhapur, with Core Diagnostics integration on track for Q1FY27. Network expanded to ~750 towns with ~5,000 service points.